West Lafayette, IN, United States of America

Wayne Douglas Luke

USPTO Granted Patents = 22 (Patent Applications = 6)

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 2.5

ph-index = 6

Forward Citations = 119(Granted Patents)

Location History:

Lafayette, IN (US) (2017)
West Lafayette, IN (US) (1981 - 2023)

Company Filing History:

15 out of 4,442

Eli Lilly and Company

patents

3 out of 5

Phosplatin Therapeutics Inc.

Linnaeus Therapeutics, Inc.

patents

Years Active: 1981-2023

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11760749 - Enantiomerically purified GPER agonist for use in treating disease states and conditions (2023-09-19),

2. 11154529 - Phosphaplatin liquid formulations (2021-10-26),

3. 10934277 - Enantiomerically purified GPER agonist for use in treating disease states and conditions (2021-03-02),

4. 9920045 - Solid state forms of a PDE10 inhibitor (2018-03-20),

5. 9650368 - Processes and intermediates for the preparation of a PDE10 inhibitor (2017-05-16),

6. 8859796 - Synthetic and purification methods for phosphaplatin compounds and uses thereof (2014-10-14),

7. 8846964 - Synthetic method for phosphaplatin compounds (2014-09-30),

8. 8030330 - Benzothiophenes, formulations containing same, and methods (2011-10-04),

9. 7012153 - Process for preparing benzoic acids (2006-03-14),

10. 6921827 - Process for preparing 3-aryl-benzo{b} thiophenes (2005-07-26),

11. 6894064 - Benzothiophenes, formulations containing same, and methods (2005-05-17),

12. 6797719 - Benzothiophenes, formulations containing same, and methods (2004-09-28),

13. 6653479 - Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride (2003-11-25),

14. 6458811 - Benzothiophenes formulations containing same and methods (2002-10-01),

15. 5994547 - Process for preparing benzo[b]thiophenes (1999-11-30),

Title: Wayne Douglas Luke: A Pioneer in Pharmaceutical Innovations

Introduction

Wayne Douglas Luke, based in West Lafayette, IN, is a distinguished inventor known for his extensive contributions to the field of pharmaceuticals. With a remarkable portfolio of 22 patents, he has made significant strides in developing novel compounds and innovative treatments that address various medical conditions.

Latest Patents

Among his latest innovations are two noteworthy patents. The first is titled "Enantiomerically purified GPER agonist for use in treating disease states and conditions." This patent discloses an enantiomerically purified compound SRR G-1, or its derivatives, that modulates G protein-coupled estrogen receptor activity. It also includes pharmaceutical and cosmetic compositions derived from the compound and outlines methods for treating or preventing disease states in humans and animals. The second patent focuses on "Phosphaplatin liquid formulations," which details pharmaceutical compositions of phosphaplatin compounds, specifically buffered stable liquid formulations of pyrodach-2 ready for use in cancer treatment, along with methods of preparation.

Career Highlights

Wayne has had an impressive career, having worked with leading pharmaceutical companies such as Eli Lilly and Company and Phosplatin Therapeutics Inc. His role in these organizations has allowed him to harness cutting-edge research and translate it into viable therapeutic solutions, significantly impacting the pharmaceutical landscape.

Collaborations

Throughout his career, Wayne has collaborated with notable colleagues, including David W. Hoard and Gordon Nelson Arbuthnot. These partnerships have fostered an environment of innovation and advanced research, contributing to the success of the projects they have undertaken.

Conclusion

Wayne Douglas Luke stands out as an accomplished inventor whose work continues to influence the pharmaceutical industry. His patents not only showcase his inventive prowess but also reflect his commitment to advancing medical science through innovative solutions. With ongoing collaborations and a dedication to research, his future endeavors promise to bring further developments in treating complex medical conditions.

This text is generated by artificial intelligence and may not be accurate.